Enhanced AI Tools by Paige Reduce Subjectivity and Manual Tasks in Breast Cancer Diagnosis

Paige is bolstering its suite of AI-driven solutions to aid pathologists in breast cancer diagnosis, aiming to reduce subjectivity and the laborious nature of the manual analysis. In March of last year, the Paige Breast Suite was unveiled, which includes Paige Breast Detect, Paige Breast Neoplasm, Paige Breast Mitosis, Paige Breast Lymph Node, and HER2Complete. This suite has played a significant role in advancing AI-enabled radiology and pathology tools. One notable feature of the suite is an AI-powered tool specifically developed for researchers to identify instances of breast cancer that have metastasized to adjacent lymph nodes.

Building upon this technology, Paige seeks to support all aspects of breast cancer diagnosis and simplify pathologists’ day-to-day tasks. Dr. David Klimstra, founder and chief medical officer at Paige, emphasizes the company’s commitment to delivering the highest level of patient care. The suite’s latest additions, Neoplasm and Mitosis detection, empower pathologists by enhancing efficiency and confidence in routine responsibilities like mitotic counting, a crucial component for determining tumor grade known for its subjectivity and tedium.

Mitotic counting involves measuring density and growth and plays a pivotal role in diagnosis. The enhanced suite incorporates an AI-powered tool specifically designed for mitotic counting. Additionally, Paige Breast Detect and Neoplasm assist pathologists in prioritizing slide and case reviews, improving workflow, and ensuring early attention to critical cases.

How does Breast Suite improve Breast Cancer Diagnosis?

• The Paige Breast Suite shares the same core technology that earned Paige FDA approval for its Prostate Detect solution.
•  The company developed its technology based on thousands of slides from numerous global institutions. Working alongside pathologists’ interpretations, the platform identifies groupings of tumor cells using AI, aiming to enhance accuracy and efficiency by highlighting all suspicious areas, including easily missed micrometastases, for pathologists to review.

The field of pathology has faced challenges due to a decrease in young professionals pursuing diagnostic specialties like radiology and pathology. While experts reassure new graduates that diagnostic technologies will remain human-centric, concerns about AI’s impact on the future of pathology persist. Dr. Klimstra highlights the scarcity of pathologists to meet the growing demands of breast cancer diagnosis and emphasizes that Paige addresses this shortage by supporting diagnosis while boosting confidence, reducing false negatives, and improving pathologists’ efficiency.

Breast cancer is the leading cancer among American women and the primary cause of death in this demographic. Industry players have turned to breakthrough AI technologies as a means to achieve earlier and more accurate diagnoses. Paige commenced the year by partnering with tech giant Microsoft, securing investment for the development and deployment of its offerings. Paige also adopted Microsoft Azure as its cloud provider, hosting its FDA-cleared whole-slide image viewer, FullFocus. This collaboration grants Paige the title of Microsoft Cloud for Healthcare partner, enabling Microsoft to enhance its healthcare offerings.

In March, Paige expanded its partnership with Leica Biosystems to enhance the utilization of image management and AI in global digital pathology workflows. Paige has been chosen by Leica as the preferred provider for digital pathology image management and viewing software-as-a-service.

Also, read: WHO Calls For Caution in Using AI in Healthcare